MIRA INFORM REPORT

 

 

Report Date :

18.04.2012

 

IDENTIFICATION DETAILS

 

Name :

AGILA SPECIALTIES PRIVATE LIMITED (w.e.f 02.07.2010)

 

 

Formerly Known As :

STRIDES SPECIALTIES PRIVATE LIMITED (we.f 20.04.2009)

 

QUANTUM LIFE SCIENCES PRIVATE LIMITED

 

 

Registered Office :

“Strides House”, Bilekahalli, Bannerghatta Road, Bangalore – 560076, Karnataka

 

 

Country :

India

 

 

Financials (as on) :

31.12.2010

 

 

Date of Incorporation :

03.03.2004

 

 

Com. Reg. No.:

08-033503

 

 

Capital Investment / Paid-up Capital :

Rs.171.000 Millions

 

 

CIN No.:

[Company Identification No.]

U02429KA2004PTC033503

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

Manufactures and Markets Pharmaceutical Products Including Penicllin, Oncology Drugs and Sterile Injectables.

 

 

No. of Employees :

Not Available

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B (28)

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Maximum Credit Limit :

USD 2600000

 

 

Status :

Moderate

 

 

Payment Behaviour :

Slow

 

 

Litigation :

Clear

 

 

Comments :

Subject is a subsidiary of Strides Arcolab Limited. It is an established company having moderate track. Profitability of the company appears to be under pressure. There appears some accumulated losses recorded by the company. However, trade relations are reported as fair. Business is active. Payments are reported to be slow.

 

The company can be considered for business dealings with some caution.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – September 30, 2011

 

Country Name

Previous Rating

(30.06.2011)

Current Rating

(30.09.2011)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LOCATIONS

 

Registered Office :

“Strides House”, Bilekahalli, Bannerghatta Road, Bangalore – 560076, Karnataka, India

Tel. No.:

91-80-66580734

Fax No.:

91-80-66580800

E-Mail :

Pratap.rudra@stridersarco.com

Kannan.n@stridesarco.com

 

 

Factory  :

Anekal Taluk Link Road Industrial Area, Bangalore – 562106, Karnataka, India

 

 

DIRECTORS

 

As On 27.05.2011

 

Name :

Mr. Arun Kumar Pillai

Designation :

Director

Address :

E 101, Adarsh Residency, Jayanagar 8th Block, Bangalore – 560082, Karnataka, India

Date of Birth/Age :

25.03.1961

Date of Appointment :

03.03.2004

DIN No.:

00084845

 

Other Directorship:

S.No.

CIN

Name of the Company

Current designation of the director

Date of appointment at current designation

Original date of appointment

Date of cessation

Company Status

Defaulting status

1

L24230MH1990PLC057062

STRIDES ARCOLAB LIMITED

Managing director

24-05-04

28-06-90

-

Active

NO

2

U24231KA1994PTC047003

ARCOLAB (INDIA) PRIVATE LIMITED

Director

28-03-94

28-03-94

-

Amalgamated

NO

3

U73100KA1999PTC026027

VEDIC ELEMENTS PRIVATE LIMITED

Director

03-12-99

03-12-99

02-10-09

Amalgamated

NO

4

U24110MH2002PLC136868

SEQUENT SCIENTIFIC LIMITED

Director

16-08-02

16-08-02

-

Amalgamated

NO

5

U02429KA2004PTC033503

AGILA SPECIALTIES PRIVATE LIMITED

Director

03-03-04

03-03-04

-

Active

NO

6

U72200KA1996PTC020663

NOUS INFOSYSTEMS PRIVATELIMITED

Director

30-09-05

30-09-05

-

Active

NO

7

U74140DL2006PTC146649

PATSYS CONSULTING PRIVATE LIMITED

Director

21-02-06

21-02-06

-

Active

NO

8

U33111MH2002PTC212925

AGNUS HOLDINGS PRIVATE LIMITED

Director

27-04-06

27-04-06

-

Active

NO

9

U24117MH2007PLC210962

FRAXIS LIFE SCIENCES LIMITED

Director

12-01-07

12-01-07

-

Amalgamated

NO

10

U24231TN1996PLC035068

GRANDIX PHARMACEUTICALS LIMITED

Director

28-09-07

20-01-07

-

Amalgamated

NO

11

U72200AP2004PTC042572

GOOSE TECHNOLOGIES PRIVATE LIMITED

Director

29-09-07

04-08-07

07-11-11

Active

NO

12

U24232KA2007PLC043599

ONCO THERAPIES LIMITED

Director

14-08-07

14-08-07

10-03-08

Active

NO

13

U24232KA2007PLC042483

SEQUENT RESEARCH LIMITED

Director

22-02-08

22-02-08

-

Active

NO

14

U15549KA2006PTC039556

MANDALA VALLEY VINEYARDS PRIVATE LIMITED

Director

18-09-08

18-09-08

-

Active

NO

15

U67190KA2010PTC054613

TRIUMPH FINCAP VENTURES PRIVATE LIMITED

Director

29-07-10

29-07-10

-

Active

NO

16

U70102MH2011PTC224475

SANTO PROPERTIES PRIVATE LIMITED

Director

29-11-11

29-11-11

-

Active

NO

 

Name :

Mr. Venkatraman Subramanian Iyer

Designation :

Director

Address :

L-204, Mantri Woodlands, Arekere Bannerghatta Road, Bangalore – 560076, Karnataka, India

Date of Birth/Age :

18.03.1957

Date of Appointment :

31.03.2006

DIN No.:

00408092

 

Other Directorship:

S.No.

CIN

Name of the Company

Current designation of the director

Date of appointment at current designation

Original date of appointment

Date of cessation

Company Status

Defaulting status

1

U24231KA2003PTC039016

MEDGENE PHARMACEUTICALS PRIVATE LIMITED

Director

14-06-06

03-05-05

-

Amalgamated

NO

2

U02429KA2004PTC033503

AGILA SPECIALTIES PRIVATE LIMITED

Director

14-06-06

31-03-06

-

Active

NO

3

U24231TZ1986PLC008788

GLOBAL REMEDIES LIMITED

Director

19-06-07

26-03-07

27-11-08

Amalgamated

NO

4

U24230KA2007PTC042337

HIGHER PHARMATECH PRIVATE LIMITED

Director

02-04-07

02-04-07

-

Active

NO

5

U24232KA2007PLC043599

ONCO THERAPIES LIMITED

Director

30-09-08

10-03-08

-

Active

NO

6

U24231TN1996PLC035068

GRANDIX PHARMACEUTICALS LIMITED

Additional director

16-03-09

16-03-09

-

Amalgamated

NO

7

L24230MH1990PLC057062

STRIDES ARCOLAB LIMITED

Whole-time director

31-05-10

19-01-10

-

Active

NO

 

 

Name :

Mr. Srinivasan Rangan Thirukandalam

Designation :

Director

Address :

# 201,”Greenis the Colour”, I Block, 3rd Main, 5th Cross, Bilekahalli Dollar Layout, BTM II Stage, Bangalore – 560076, Karnataka, India

Date of Birth/Age :

14.06.1965

Date of Appointment :

16.03.2009

DIN No.:

02578755

 

Other Directorship:

S.No.

CIN

Name of the Company

Current designation of the director

Date of appointment at current designation

Original date of appointment

Date of cessation

Company Status

Defaulting status

1

U24231TZ1986PLC008788

GLOBAL REMEDIES LIMITED

Director

05-05-09

16-03-09

-

Amalgamated

NO

2

U24296KA2008PTC045588

QUANTUM REMEDIES PRIVATE LIMITED

Director

05-05-09

16-03-09

-

Amalgamated

NO

3

U24231KA2003PTC039016

MEDGENE PHARMACEUTICALS PRIVATE LIMITED

Director

05-05-09

16-03-09

-

Amalgamated

NO

4

U02429KA2004PTC033503

AGILA SPECIALTIES PRIVATE LIMITED

Director

05-05-09

16-03-09

-

Active

NO

5

U24232TN2001PLC047875

GRANDIX LABORATORIES LIMITED

Additional director

16-03-09

16-03-09

-

Amalgamated

NO

6

U24231TN1996PLC035068

GRANDIX PHARMACEUTICALS LIMITED

Additional director

16-03-09

16-03-09

-

Amalgamated

NO

7

U73100KA2009PTC049535

STRIDES TECHNOLOGY AND RESEARCH PRIVATE LIMITED

Director

06-04-09

06-04-09

-

Under Process of Striking off

NO

 

 

KEY EXECUTIVES

 

Name :

Mr. Pratap Rudra Bhuvanagiri

Designation :

Company Secretary

Address :

413, 5th B Main Road, HRBR Layout, 2nd Block, Kalyan Nagar, Bangalore – 560043, Karnataka, India

Date of Birth/Age :

27.06.1982

Date of Appointment :

11.05.2009

Pan No.:

AWDPP9893R

 

 

Name :

Mr. Venkatesh

Designation :

Accounts Department

 

 

Name :

Mr. Mohan Babu

Designation :

Manager

Address :

41/B, Hosahally Handenahally Post, Anekal Taluk, Bangalore – 562125, Karnataka, India

Date of Birth/Age :

22.07.1971

Date of Appointment :

26.07.2006

Pan No.:

ANUPM8158Q

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

As On 27.05.2011

 

Names of Shareholders

 

No. of Shares

Strides Arcolab Limited – India

 

15099990

N T Venkatesha

 

5

Kannan N

 

5

Total

 

15100000

 

 

Names of Shareholders

 

No. of Shares Preference Shares 

Strides Arcolab Limited – India

 

200000

 

 

As On 27.05.2011

 

Equity Share Break up (Percentage of Total Equity)

 

Category

Percentage

Bodies corporate

100.00

Total

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufactures and Markets Pharmaceutical Products Including Penicllin, Oncology Drugs and Sterile Injectables.

 

 

Products :

Item Code No

Product Description

3003

Pharmaceutical Formulations

 

 

 

 

PRODUCTION STATUS (AS ON 31.12.2010)

 

Particulars

 

 

Unit

Installed Capacity

Betalactam Plant

 

 

 

 

Capsules and tables

 

 

Numbers in Millions

350.000

Dry powder vials

 

 

Numbers in Millions

20.000

Sterile products

 

 

 

 

Ampoules

 

 

Numbers in Millions

48.000

Liquid vials

 

 

Numbers in Millions

48.000

Pre-filled syringes

 

 

Numbers in Millions

7.500

Dry powder vials

 

 

Numbers in Millions

16.000

Sterile formulations facility

 

 

 

 

Liquid vials

 

 

Numbers in Millions

86.350

Dry powder vials

 

 

Numbers in Millions

54.700

 

Installed Capacities are as certified by the management and relied upon by the auditors. The Installed Capacities serve multiple purposed and will vary according to product mix.

** Not applicable as the products have been delicensed.

 

Actual Production

 

Particulars

Units

Actual Production

Capsules

Qty (In ‘000’s)

23812132

Injections

Qty (In ‘000’s)

98755444

 

 

GENERAL INFORMATION

 

No. of Employees :

Not Available

 

 

Bankers :

  • Central Bank of India – Corporate Finance Branch, MMO Building, 1st Floor, M.G. Road, Fort, Mumbai – 400023, Maharashtra, India
  • Axis Bank Limited, 2nd Floor-E, Axis House, Bombay Dyeing Mill Compound, Panduranga Budhkar Marg, Worli, Mumbai - 400025, Maharashtra, India

 

 

Facilities :

Secured Loans

31.12.2010 (Rs. In Millions)

31.12.2009 (Rs. In Millions)

Short Term Loan

 

 

-          From Banks

700.000

0.000

Total

700.000

0.000

 

Unsecured Loans

31.12.2010 (Rs. In Millions)

31.12.2009 (Rs. In Millions)

Inter Corporate Loans:

 

 

-          Long Term

2215.446

0.000

-          Short Term

0.000

2287.414

Total

2215.446

2287.414

 

Notes:

 

1) Short term loan from banks are working capital loans, which are secured by a pari passu first charge on the company’s movable property.

 

2) Long Term Loan due within one year Rs.Nil.

 

 

 

Banking Relations :

--

 

 

Auditors :

 

Name :

Deloitte Haskins and Sells

Chartered Accountants 

Address :

Deloitte Centre, Anchorage II, 100/2, Richmond Road, Bangalore – 560025, Karnataka, India

Pan No.:

AACFD3771D

 

 

Holding Company :

  • Strides Arcolab Limited

      CIN: L24230MH1990PLC057062

 

 

Wholly owned subsidiaries:

Direct Holding

  • Strides Specialties (Holding) Limited

 

Indirect Holding

  • Strides Specialties (Holdings) Limited, Cyprus
  • Strides Specialties (Cyprus) Limited, Cyprus

 

 

Other Subsidiaries:

  • Inbiopro Solutions Private Limited, India (w.e.f November 25,2010)

 

 

Fellow Subsidiaries:

  • Arcolab Limited SA, Switzerland
  • Strides Technology and Research Private Limited, India
  • Agila Specialties Private Limited (formerly Strides Specialties Private Limited), India
  • Starsmore Limited, Cyprus
  • Strides Africa Limited, British Virgin Islands
  • Strides Arcolab International Limited, U.K (SAIL)
  • Onco Therapies Limited, India
  • Pharma Strides Canada Corporation, Canada
  • Linkace Limited, Cyprus
  • Linkace Investments PTY Limited, Australia
  • Plus Farma ehf, Iceland
  • Farma Plus AS , Norway
  • Strides Specialties (Holdings) Limited, Mauritius
  • Strides Specialties (Holdings) Cyprus Limited (previously known as Powercoast Limited), Cyprus
  • Strides Pharmaceuticals (Holdings) Limited, Mauritius
  • Strides Pharmaceuticals (Mauritius) Limited, Mauritius
  • Strides Specialty (Cyprus) Limited. Cyprus
  • Co Pharma Limited, UK 
  • Strides Arcolab Polska Sp.z o.o, Poland
  • Onco Laboratories Limited (formerly Powercliff Limited), Cyprus
  • Strides Arcolab UK Limited, UK 
  • Agila Especialidades Farmaceuticas Ltda, Brazil Agila Specialties (Malaysia) SDN BHD, Malaysia Strides Australia Pty Limited, Australia
  • Strides Inc. USA           
  • Strides Farmaceutica Participacoes Ltda, Brazil
  • Strides Farmaceutica Participacoes Ltda, Brazil
  • Strides Pharma (Cyprus) Limited, Cyprus
  • Ascent Pharmahealth Limited, Australia
  • Ascent Pharmahealth Asia Pte Limited, Singapore Beltapharm S.p.A., Italy
  • Drug Houses of Australia (Asia) Re. Limited, Singapore
  • Co Pharma Limited, UK (uptoJune30, 2010)        
  • Formule Naturelle (Pty) Limited , South Africa (up to 1s1 July 2010)
  • Ascent Pharma Pty Limited (earlier known as Genepharm Pty Limited), Australia
  • Pharmasave Australia Pty Limited, Australia
  • Strides S.A. Pharmaceuticals Pty. Limited, South Africa
  • Inbiopro Solutions Private Limited, India (w.e.f. November 25, 2010)
  • Ascent Pharmacy Services Pty Limited, Australia (w.e.f. January 29,2010)
  • Ascent Pharmaceuticals Limited (earlier known as Genepharm (New Zealand) Limited),New Zealand
  • African Pharmaceutical Development Company, Cameroon (w.e.f. January 01,2010)
  • Green Cross Pharma Pte Limited, Singapore (up to 1st January 2010)
  • Ephos - 106 Produtos Hospitalaries Ltda Me, Brazil (w.e.f. November 2010) Ascent Pharmahealth Asia (Hong Kong) Limited (earlier known as Strides Arcolab Hong Kong Limited), Hong Kong
  • Ascent Pharmahealth Asia (Malaysia) SDN BHD (earlier known as Strides Arcolab Malaysia SDN. BHD), Malaysia
  • Ascent Pharmahealth Asia (B) SDN BHD (earlier known as Strides Arcolab SDN BHD, Brunei)
  • Strides CIS Limited, Cyprus (Previously known as Raycom Limited)
  • Strides Vital Nigeria Limited, Nigeria

 

 

Related Parties  :

·         Agnus Global Holdings Private Limited, India

·         Arcolab (India) Private Limited (merged with Agnus Holdings Private Limited w.e.f. March 24, 2010)   

·         Atma Projects, India

·         Higher Pharmatech Private Limited, India

·         Caryl Pharma Private Limited (merged with Agnus Holdings Private Limited w.e.f. March 24, 2010)

·         Chayadeep Properties Private Limited, India

·         Agnus Global Holdings Pte Limited, Singapore

·         Agnus Holdings Private Limited, India

·         Fraxis Life Sciences Limited, India

·         Atma Enterprises LLP, India

·         Chayadeep Ventures LLP, India

·         Qualichem Capital LLP, India

·         Agnus Capital LLP, India

·         Triumph Ventures LLP, India

 


 

CAPITAL STRUCTURE

 

As On 31.12.2010

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

20000000

Equity Shares

Rs. 10/- each

Rs.200.000 Millions

200000

0.1% Redeemable Preference Shares

Rs. 100/- each

Rs. 20.000 Millions

 

Total

 

Rs.220.000 Millions

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

15100000

Equity Shares

Rs. 10/- each

Rs.151.000 Millions

200000

0.1% Redeemable Preference Shares

Rs. 100/- each

Rs. 20.000 Millions

 

Total

 

Rs.171.000 Millions

 

Note:

Entire share capital is held by – Strides Arcolab Limited, the Holding Company.


 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.12.2010

31.12.2009

31.12.2008

SHAREHOLDERS FUNDS

 

 

 

1] Share Capital

171.000

146.000

146.000

2] Monies Pending Allotment

0.000

1000.000

0.000

3] Reserves & Surplus

1155.000

180.000

180.000

4] (Accumulated Losses)

(677.955)

(115.824)

(94.790)

NETWORTH

648.045

1210.176

231.210

LOAN FUNDS

 

 

 

1] Secured Loans

700.000

0.000

0.000

2] Unsecured Loans

2215.446

2287.414

0.000

TOTAL BORROWING

2915.446

2287.414

0.000

DEFERRED TAX LIABILITIES

0.000

22.237

22.240

 

 

 

 

TOTAL

3563.491

3519.827

253.450

 

 

 

 

APPLICATION OF FUNDS

 

 

 

 

 

 

 

FIXED ASSETS [Net Block]

2377.384

2343.336

309.820

Capital work-in-progress

591.706

458.451

0.000

 

 

 

 

INVESTMENT

161.626

12.750

7.600

DEFERREX TAX ASSETS

0.000

0.000

0.000

 

 

 

 

CURRENT ASSETS, LOANS & ADVANCES

 

 

 

 

Inventories

424.221
398.457

6.130

 

Sundry Debtors

616.438
610.246

0.020

 

Cash & Bank Balances

75.802
6.739

0.000

 

Other Current Assets

338.217
421.063

3.610

 

Loans & Advances

443.936
508.947

128.910

Total Current Assets

1898.614
1945.452

138.680

Less : CURRENT LIABILITIES & PROVISIONS

 

 

 

 

Sundry Creditors

1273.361

883.310

198.580

 

Other Current Liabilities

234.896
307.941

0.520

 

Provisions

56.499
48.911

3.550

Total Current Liabilities

1564.756
1240.162

202.650

Net Current Assets

333.858
705.290

(63.970)

 

 

 

 

MISCELLANEOUS EXPENSES

98.917

0.000

0.000

 

 

 

 

TOTAL

3563.491

3519.827

253.450

 


PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.12.2010

31.12.2009

31.12.2008

 

SALES

 

 

 

 

 

Income

2927.504

104.177

96.940

 

 

Other Income

19.501

1.859

0.000

 

 

TOTAL                                     (A)

2947.005

106.036

96.940

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Materials Consumed

1488.832

22.962

27.980

 

 

Increase/Decrease in stock

17.543

0.000

0.000

 

 

Personnel Cost

515.329

17.373

16.000

 

 

Operating and other expenses

862.250

49.137

44.950

 

 

TOTAL                                     (B)

2883.954

89.472

88.930

 

 

 

 

 

Less

PROFIT BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B)      (C)

63.051

16.564

8.010

 

 

 

 

 

Less

FINANCIAL EXPENSES                         (D)

394.569

2.556

1.840

 

 

 

 

 

 

PROFIT BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D)                                       (E)

(331.518)

14.008

6.170

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION                     (F)

195.758

35.032

33.700

 

 

 

 

 

 

PROFIT BEFORE TAX (E-F)                               (G)

(527.276)

(21.024)

(27.530)

 

 

 

 

 

Less

TAX                                                                  (I)

22.435

0.010

0.180

 

 

 

 

 

 

PROFIT AFTER TAX (G-I)                                  (J)

(504.841)

(21.034)

(27.710)

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD

(115.824)

(94.790)

(67.080)

 

 

 

 

 

 

INCLUDED ON AMALGAMATION  

(57.291)

0.000

0.000

 

 

 

 

 

 

BALANCE CARRIED TO THE B/S

(677.956)

(115.824)

(94.790)

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

 

 

 

 

 

FOB Value of exports of goods / contract

2598.590

51.613

9.970

 

 

Development and licensing Income

176.253

0.000

0.000

 

 

Other Income

19.474

0.000

0.000

 

TOTAL EARNINGS

2794.317

51.613

9.970

 

 

 

 

 

 

IMPORTS

 

 

 

 

 

Raw Materials

836.040

10.080

13.940

 

 

Capital Goods

127.134

0.000

6.210

 

 

Other Goods

36.876

0.000

0.000

 

TOTAL IMPORTS

1000.050

10.080

20.150

 

 

 

 

 

 

Earnings Per Share (Rs.)

(33.43)

(1.67)

(2.20)

 

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.12.2010

31.12.2009

31.12.2008

PAT / Total Income

(%)

(17.13)

(19.84)

(28.58)

 

 

 

 

 

Net Profit Margin

(PBT/Sales)

(%)

(18.01)

(20.18)

(28.40)

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

(12.33)

(0.49)

(6.14)

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

(0.81)

(0.02)

(0.12)

 

 

 

 

 

Debt Equity Ratio

(Total Liability/Networth)

 

6.91

2.91

0.88

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

1.21

1.57

0.68

 

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Check List by Info Agents

Available in Report (Yes / No)

1) Year of Establishment

Yes

2) Locality of the firm

Yes

3) Constitutions of the firm

Yes

4) Premises details

No

5) Type of Business

Yes

6) Line of Business•

Yes

7) Promoter’s background

Yes

8) No. of employees

No

9) Name of person contacted

No

10) Designation of contact person

No

11) Turnover of firm for last three years

Yes

12) Profitability for last three years

Yes

13) Reasons for variation <> 20%

--

14) Estimation for coming financial year

No

15) Capital in the business

Yes

16) Details of sister concerns

Yes

17) Major suppliers

No

18) Major customers

No

19) Payments terms

No

20) Export / Import details (if applicable)

No

21) Market information

--

22) Litigations that the firm / promoter

--

23) Banking Details

Yes

24) Banking facility details

Yes

25) Conduct of the banking account

--

26) Buyer visit details

--

27) Financials, if provided

Yes

28) Incorporation details, if applicable

Yes

29) Last accounts filed at ROC

Yes

30) Major Shareholders, if available

Yes

 

Operational Highlights:

 

Total revenue of the company stood at Rs. 105.580 Million for the year ended 31.12.2009 as against Rs. 96.940 Million for the previous year ended 31.12.2008. The company incurred a net loss of Rs. 21.030 Million during the year.

 

Contingent Liabilities:

Estimated amount of contracts remaining to be executed on capital account and not provided for Rs. 114.118 Millions (Previous Year - Rs. 213.813 Millions)

The Company has given the corporate guarantees to financial institution towards credit facilities/ advances, on behalf of the Holding Company up to Rs. 250.000 Millions (Previous year Nil). Subsequent to the year end, the mentioned corporate guarantee has been revoked on repayment of such credit facilities / advances by the Holding company.

Bank Guarantee for Rs. 1.000 Millions and Bond amounting to Rs. 200.000 Millions favouring the Commissioner of Customs and Central Excise for removal of goods and capital items without payment of duty.

 

Bankers Charges Report as per Registry:

 

Corporate identity number of the company

U02429KA2004PTC033503

Name of the company

AGILA SPECIALTIES PRIVATE LIMITED

Address of the registered office or of the principal place of  business in India of the company

"Strides House", Bilekahalli, Bannerghatta Road, Bangalore – 560076, Karnataka, India

E-mail : Pratap.Rudra@stridesarco.com

This form is for

Creation of charge

Type of charge

Movable Property

Particular of charge holder

Axis Bank Limited, 2nd Floor-E, Axis House, Bombay Dyeing Mill Compound, Panduranga Budhkar Marg, Worli, Mumbai - 400025, Maharashtra, India

E-mail : kulkarni.makarand@axisbank.com

Nature of instrument creating charge

By way of Deed of Hypothecation executed by subject in favor of Axis Bank Limited, Mumbai, acting as Onshore Security Trustee for Axis Bank Limited, Hong Kong ( the Lender) to the tune of USD  50 Million (Approx Rs. 2275.250 Millions)  to facilitate Strides Arcolab Limited

Date of instrument Creating the charge

24.10.2011

Amount secured by the charge

Rs.2275.250 Millions

Brief of the principal terms an conditions and extent and operation of the charge

Rate of Interest

The percentage rate per annum equal to the aggregate of the applicable margin and LIBOR.

 

Terms of Repayment –

The borrower has to repay the loan in 20 quarterly installments as fully set out in the Facility Agreement.

 

Margin

4.25% per annum, as adjusted in accordance with Clause 8.4, Clause 8.5 or Clause 8.6 of the Facility Agreement.

 

Extent and Operation of the charge

Second ranking security interest by way of hypothecation on all present and future movable fixed assets of subject in favor security trustee.

 

Others

Subject is providing security of its assets to Axis Bank Limited for the borrowing of Strides Arcolab Limited (the Parent Company).

Particulars of the property charged

All the movable fixed assets of Agila including its movable plant and machinery, machinery spares, tools and accessories and other movables, both present and future etc.

 

 

Fixed Assets:

 

  • Leasehold land
  • Building
  • Furniture and fixtures
  • Office equipment and computers
  • Plant and machinery
  • Motor vehicle
  • Registrations and brands
  • Software licenses

 

 

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No records exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                  None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 

 

 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.51.63

UK Pound

1

Rs.81.94

Euro

1

Rs.67.65

 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

4

PAID-UP CAPITAL

1~10

4

OPERATING SCALE

1~10

3

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

3

--PROFITABILIRY

1~10

2

--LIQUIDITY

1~10

4

--LEVERAGE

1~10

3

--RESERVES

1~10

2

--CREDIT LINES

1~10

3

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

NO

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

TOTAL

 

28

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

-

NB

                                       New Business

-

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.